Importer of Controlled Substances Application: Midas Pharmaceuticals, Inc., 35974-35975 [2015-15331]

Download as PDF mstockstill on DSK4VPTVN1PROD with NOTICES 35974 Federal Register / Vol. 80, No. 120 / Tuesday, June 23, 2015 / Notices Rules of Practice and Procedure (19 CFR 210.8(b)). FOR FURTHER INFORMATION CONTACT: Lisa R. Barton, Secretary to the Commission, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436, telephone (202) 205–2000. The public version of the complaint can be accessed on the Commission’s Electronic Document Information System (EDIS) at EDIS,1 and will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436, telephone (202) 205–2000. General information concerning the Commission may also be obtained by accessing its Internet server at United States International Trade Commission (USITC) at USITC.2 The public record for this investigation may be viewed on the Commission’s Electronic Document Information System (EDIS) at EDIS.3 Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205–1810. SUPPLEMENTARY INFORMATION: The Commission has received a complaint and a submission pursuant to section 210.8(b) of the Commission’s Rules of Practice and Procedure filed on behalf of Reynolds Presto Products Inc. on June 17, 2015. The complaint alleges violations of section 337 of the Tariff Act of 1930 (19 U.S.C. 1337) in the importation into the United States, the sale for importation, and the sale within the United States after importation of certain resealable packages with slider devices. The complaint names as respondents Interplast Group, Ltd. of Livingston, NJ and Minigrip, LLC of Alpharetta, GA. The complainant requests that the Commission issue a permanent general exclusion order, cease and desist orders, and a bond upon respondents’ alleged infringing articles during the 60-day Presidential review period pursuant to 19 U.S.C. § 1337(j). Proposed respondents, other interested parties, and members of the public are invited to file comments, not to exceed five (5) pages in length, inclusive of attachments, on any public interest issues raised by the complaint or section 210.8(b) filing. Comments should address whether issuance of the 1 Electronic Document Information System (EDIS): https://edis.usitc.gov. 2 United States International Trade Commission (USITC): https://edis.usitc.gov. 3 Electronic Document Information System (EDIS): https://edis.usitc.gov. VerDate Sep<11>2014 18:39 Jun 22, 2015 Jkt 235001 relief specifically requested by the complainant in this investigation would affect the public health and welfare in the United States, competitive conditions in the United States economy, the production of like or directly competitive articles in the United States, or United States consumers. In particular, the Commission is interested in comments that: (i) Explain how the articles potentially subject to the requested remedial orders are used in the United States; (ii) identify any public health, safety, or welfare concerns in the United States relating to the requested remedial orders; (iii) identify like or directly competitive articles that complainant, its licensees, or third parties make in the United States which could replace the subject articles if they were to be excluded; (iv) indicate whether complainant, complainant’s licensees, and/or third party suppliers have the capacity to replace the volume of articles potentially subject to the requested exclusion order and/or a cease and desist order within a commercially reasonable time; and (v) explain how the requested remedial orders would impact United States consumers. Written submissions must be filed no later than by close of business, eight calendar days after the date of publication of this notice in the Federal Register. There will be further opportunities for comment on the public interest after the issuance of any final initial determination in this investigation. Persons filing written submissions must file the original document electronically on or before the deadlines stated above and submit 8 true paper copies to the Office of the Secretary by noon the next day pursuant to section 210.4(f) of the Commission’s Rules of Practice and Procedure (19 CFR 210.4(f)). Submissions should refer to the docket number (‘‘Docket No. 3072’’) in a prominent place on the cover page and/or the first page. (See Handbook for Electronic Filing Procedures, Electronic Filing Procedures.4) Persons with questions regarding filing should contact the Secretary (202–205–2000). Any person desiring to submit a document to the Commission in confidence must request confidential treatment. All such requests should be 4 Handbook for Electronic Filing Procedures: https://www.usitc.gov/secretary/fed_reg_notices/ rules/handbook_on_electronic_filing.pdf. PO 00000 Frm 00043 Fmt 4703 Sfmt 4703 directed to the Secretary to the Commission and must include a full statement of the reasons why the Commission should grant such treatment. See 19 CFR 201.6. Documents for which confidential treatment by the Commission is properly sought will be treated accordingly. All nonconfidential written submissions will be available for public inspection at the Office of the Secretary and on EDIS.5 This action is taken under the authority of section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and of sections 201.10 and 210.8(c) of the Commission’s Rules of Practice and Procedure (19 CFR 201.10, 210.8(c)). Issued: June 18, 2015. By order of the Commission. Lisa R. Barton, Secretary to the Commission. [FR Doc. 2015–15368 Filed 6–22–15; 8:45 am] BILLING CODE 7020–02–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Importer of Controlled Substances Application: Midas Pharmaceuticals, Inc. ACTION: Notice of application. Registered bulk manufacturers of the affected basic class, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.34(a) on or before July 23, 2015. Such persons may also file a written request for a hearing on the application pursuant to 21 CFR 1301.43 on or before July 23, 2015. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODXL, 8701 Morrissette Drive, Springfield, Virginia 22152. Request for hearings should be sent to: Drug Enforcement Administration, Attention: Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, DATES: 5 Electronic Document Information System (EDIS): https://edis.usitc.gov. E:\FR\FM\23JNN1.SGM 23JNN1 Federal Register / Vol. 80, No. 120 / Tuesday, June 23, 2015 / Notices incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control (‘‘Deputy Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.34(a), this is notice that on January 12, 2015, Midas Pharmaceuticals, Inc., 300 Interpace Parkway, Suite 420, Parsippany, New Jersey 07054–1100 applied to be registered as an importer of remifentanil (9739), a basic class of controlled substance listed in schedule II. The company plans to import the listed controlled substance in order to bulk manufacture controlled substance in Active Pharmaceutical Ingredient (API) form. The company distributes the manufactured APIs in bulk to its customers. Dated: June 12, 2015. Joseph T. Rannazzisi, Deputy Assistant Administrator. National Archives and Records Administration (NARA). ACTION: Presidential Records Act notice of proposed disposal of Reagan and George H.W. Bush administration disaster recovery backup tapes; final agency action. destruction, and a synopsis of the completed restoration projects. NARA has determined that the backup tapes do not warrant further retention. All required backup restoration projects have taken place, NARA is preserving and permanently retaining the restored records, and we have identified no further need to preserve or maintain the backup tapes. This notice constitutes a final agency action, as described in 44 U.S.C. 2203(g)(3), and NARA will dispose of the described backup tapes on or after the date below. DATES: NARA will dispose of the backup tapes on or after August 24, 2015. FOR FURTHER INFORMATION CONTACT: Director of Presidential Libraries Susan K. Donius, by mail at National Archives and Records Administration, Suite 2200; 8601 Adelphi Road; College Park, Maryland 20740–6001, by telephone at (301) 837–3250, by fax at (301) 837– 3199, or by email at elizabeth.fidler@nara.gov. SUPPLEMENTARY INFORMATION: Public comments: NARA published a ‘‘Presidential Records Act notice of proposed disposal of Reagan and George H.W. Bush administration disaster recovery backup tapes; request for public comment’’ on February 6, 2015, in the Federal Register (80 FR 6770) for a 45-day comment period. NARA received one written comment, in which a concerned citizen suggested that NARA should retain the ‘‘documentation’’ so that it can be made available to the public. NARA has considered the comment. As described in the notice of proposed disposal, NARA is retaining the recovered records from the backup tapes. All the Presidential and Federal records that were on the tapes have been restored, and NARA is permanently retaining those restored records. This is in line with the commenter’s suggestion and goal, so NARA believes no further action is necessary in response to the comment and is proceeding with destruction of the backup tapes as outlined in the proposal notice. NARA is issuing final notice that it intends to dispose of several collections of disaster recovery backup tapes from the Ronald Reagan (Reagan) and George H.W. Bush (GHW Bush) administrations under the provisions of 44 U.S.C. 2203(g)(3). NARA published notice in the Federal Register (February 6, 2015 (80 FR 6770)), proposing to dispose of these backup tapes. That initial notice contains a detailed description of the tapes, the reasons for NARA action NARA will dispose of 3,071 original disaster recovery backup tapes created during the Reagan and GHW Bush administrations, and subsequent preservation copies of those media (maintained for the Professional/Office Vision software (PROFS) system, the Sperry/VAX All-in-One system, and for systems operated by the White House Situation Support Staff (WHSSS) and the White House Situation Room Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control (‘‘Deputy Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.34(a), this is notice that on February 19, 2015, Wildlife Laboratories, Inc., 1230 W. Ash Street, Suite D, Windsor, Colorado 80550 applied to be registered as an importer of the following basic classes of controlled substances: Controlled substance Etorphine (except HCl) (9056) ..... Etorphine HCl (9059) ................... [FR Doc. 2015–15331 Filed 6–22–15; 8:45 am] Schedule I II The company plans to import the listed controlled substances for sale to its customer. BILLING CODE 4410–09–P Drug Enforcement Administration Dated: June 12, 2015. Joseph T. Rannazzisi, Deputy Assistant Administrator. [Docket No. DEA–392] [FR Doc. 2015–15332 Filed 6–22–15; 8:45 am] DEPARTMENT OF JUSTICE BILLING CODE 4410–09–P Importer of Controlled Substances Application: Wildlife Laboratories, Inc. ACTION: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.34(a) on or before July 23, 2015. Such persons may also file a written request for a hearing on the application pursuant to 21 CFR 1301.43 on or before July 23, 2015. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODXL, 8701 Morrissette Drive, Springfield, Virginia 22152. Request for hearings should be sent to: Drug Enforcement Administration, Attention: Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled DATES: mstockstill on DSK4VPTVN1PROD with NOTICES NATIONAL ARCHIVES AND RECORDS ADMINISTRATION Notice of application. VerDate Sep<11>2014 18:39 Jun 22, 2015 Jkt 235001 35975 [NARA–2015–039] Office of Presidential Libraries; Disposal of Presidential Records AGENCY: SUMMARY: PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 E:\FR\FM\23JNN1.SGM 23JNN1

Agencies

[Federal Register Volume 80, Number 120 (Tuesday, June 23, 2015)]
[Notices]
[Pages 35974-35975]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-15331]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Importer of Controlled Substances Application: Midas 
Pharmaceuticals, Inc.

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic class, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration in accordance with 21 CFR 
1301.34(a) on or before July 23, 2015. Such persons may also file a 
written request for a hearing on the application pursuant to 21 CFR 
1301.43 on or before July 23, 2015.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/ODXL, 
8701 Morrissette Drive, Springfield, Virginia 22152. Request for 
hearings should be sent to: Drug Enforcement Administration, Attention: 
Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his 
authority under the Controlled Substances Act to the Administrator of 
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority 
to exercise all necessary functions with respect to the promulgation 
and implementation of 21 CFR part 1301,

[[Page 35975]]

incident to the registration of manufacturers, distributors, 
dispensers, importers, and exporters of controlled substances (other 
than final orders in connection with suspension, denial, or revocation 
of registration) has been redelegated to the Deputy Assistant 
Administrator of the DEA Office of Diversion Control (``Deputy 
Assistant Administrator'') pursuant to section 7 of 28 CFR part 0, 
appendix to subpart R.
    In accordance with 21 CFR 1301.34(a), this is notice that on 
January 12, 2015, Midas Pharmaceuticals, Inc., 300 Interpace Parkway, 
Suite 420, Parsippany, New Jersey 07054-1100 applied to be registered 
as an importer of remifentanil (9739), a basic class of controlled 
substance listed in schedule II.
    The company plans to import the listed controlled substance in 
order to bulk manufacture controlled substance in Active Pharmaceutical 
Ingredient (API) form. The company distributes the manufactured APIs in 
bulk to its customers.

    Dated: June 12, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015-15331 Filed 6-22-15; 8:45 am]
 BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.